Zhang Yaofang, Du Li, Xu Yanling, Tian Lin, Tu Peipei, Li Minggang
State Key Laboratory of Medicinal Chemical Biology, College of Life Science, Nankai University, 300071 Tianjin, China.
College of Basic Science, Tianjin Agricultural University, 300384 Tianjin, China.
Curr Pharm Biotechnol. 2017;18(10):840-848. doi: 10.2174/1389201019666171204111908.
Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) play a similar but complementary role in the regulation of glucose levels in islet β-cells. This study was aimed to develop a fusion peptide, which combines 4 tandem repeated GLP-1 and 4 tandem repeated GIP (4rolGG), and to investigate its therapeutic effect on type 2 diabetes using a diabetic mice model.
A 4rolGG expression plasmid was constructed and expressed in BL21 (DE3). By inducting with IPTG, 4rolGG was expressed at a high level, which was confirmed by SDS-PAGE electrophoresis and Western Blotting. Subsequently, 4rolGG was purified by Ni-NTA affinity chromatography and the purity of 4rolGG was up to 90%.
After oral administration of 4rolGG for 4 weeks, streptozotocin-induced diabetic mice showed a dramatic reduction in the levels of plasma glucose, GHbA1C, TC and TG, while the insulin levels were increased significantly.
